Schizophrenia

24 trials 8 recruiting MedDRA PT
24 Registered trials
8 Recruiting
17 Unique sponsors
15 Unique IMPs
18 Commercial trials
Drug classes (ATC)
— ATC code not specified 20
N Neurology/Psychiatry (ATC N) 5
R Respiratory (ATC R) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 15 substances
Phase III: 11 Phase II/III: 1 Phase II: 5 Phase IV: 2 Phase I (Other): 2 Other: 4

Filter these 24 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 24 trials

Phase III

11 trials
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    TROSPIUM CHLORIDE, XANOMELINE TARTRATE
    2025-523711-11-00 1 country n=28
    Pending
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    TROSPIUM CHLORIDE, XANOMELINE TARTRATE; XANOMELINE TARTRATE
    2025-524062-16-00 1 country n=40
    Pending
  • Gedeon Richter Plc. Commercial
    CARIPRAZINE; CARIPRAZINE HYDROCHLORIDE
    2024-513194-44-00 2 countries 2021 n=42
    Ended
  • Gedeon Richter Plc. Commercial
    CARIPRAZINE; CARIPRAZINE HYDROCHLORIDE
    2024-513222-30-00 3 countries 2020 n=39
    Recruiting
  • Karuna Therapeutics Inc. Commercial
    TROSPIUM CHLORIDE, XANOMELINE TARTRATE
    2024-510770-25-00 1 country 2023 n=65
    Ended
  • Karuna Therapeutics Inc. Commercial
    TROSPIUM CHLORIDE, XANOMELINE TARTRATE
    2024-510773-20-00 1 country 2023 n=50
    Ended
  • Neurocrine Biosciences Inc. Commercial
    VALBENAZINE DITOSYLATE 
    2022-502233-25-00 6 countries n=199
    Ended
  • Neurocrine Biosciences Inc. Commercial
    VALBENAZINE DITOSYLATE 
    2023-508433-14-00 6 countries 2022 n=192
    Ended
  • Neurocrine Biosciences Inc. Commercial
    DIRECLIDINE
    2025-521216-19-00 3 countries 2025 n=154
    Recruiting
  • Newron Pharmaceuticals S.p.A. Commercial
    EVENAMIDE
    2024-519836-18-00 9 countries 2025 n=135
    Recruiting
  • University Medical Center Utrecht Academic
    ESKETAMINE HYDROCHLORIDE
    2022-502185-24-00 4 countries n=945
    Not authorised

Phase II/III

1 trial
  • Institut National De La Sante Et De La Recherche Medicale Academic
    N,N-DIETHYL-2-(2-(4-(2[(18)F]-FLUOROETHOXY)PHENYL)5,7DIMETHYLPYRAZOLO[1,5A]PYRIMIDIN-3-YL)ACETAMIDE
    2023-504181-38-00 1 country 2025 n=75
    Recruiting

Phase II

5 trials
  • Neurocrine Biosciences Inc. Commercial
    NBI-1117570
    2025-521868-35-00 3 countries 2026 n=73
    Recruiting
  • Novartis Pharma AG Commercial
    GXV813
    2025-524058-32-00 1 country n=42
    Pending
  • Oryzon Genomics S.A. Commercial
    VAFIDEMSTAT
    2023-507372-42-00 5 countries 2021 n=239
    Recruiting
  • Recognify Life Sciences Inc. Commercial
    (2R,3S)-2-AMINO-3-HYDROXY-3-PYRIDIN-4-YL-1-PYRROLIDIN-1-YLPROPAN-1-ONE (2R,3R)-2,3-DIHYDROXYBUTANEDIOIC ACID
    2023-506570-12-01 3 countries 2024 n=164
    Ended
  • Klinikum der Universitaet Muenchen AöR Academic
    CLEMASTINE; PLACEBO
    2024-514457-30-00 1 country 2024 n=90
    Recruiting

Phase IV

2 trials
  • Masarykova Univerzita Academic
    IMP not specified
    2022-502902-33-00 1 country 2023 n=200
    Ended
  • Universitair Medisch Centrum Utrecht Academic
    IMP not specified
    2023-506602-39-00 4 countries 2024 n=310
    Recruiting

Phase I (Other)

2 trials
  • Clexio Biosciences Ltd. Commercial
    IMP not specified
    2025-521914-25-00 1 country 2025 n=110
    Ended
  • Teva Branded Pharmaceutical Products R&D LLC Commercial
    IMP not specified
    2023-505664-11-00 4 countries 2024 n=18
    Ended

Other

4 trials
  • Adamed Pharma S.A. Commercial
    IMP not specified
    2025-521400-21-00 1 country 2025 n=54
    Ended
  • Adamed Pharma S.A. Commercial
    IMP not specified
    2025-523325-18-00 1 country 2025 n=36
    Ended
  • Geneora Pharma (Shijiazhuang) Co. Ltd. Academic
    IMP not specified
    2022-502179-48-00 1 country 2023 n=170
    Ended
  • Geneora Pharma (Shijiazhuang) Co. Ltd. Academic
    IMP not specified
    2022-502179-48-00 1 country 2023 n=170
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Neurocrine Biosciences Inc. Commercial 4 Phase II, Phase III 2
Adamed Pharma S.A. Commercial 2 Other 0
Bristol-Myers Squibb Services Unlimited Company Commercial 2 Phase III 0
Gedeon Richter Plc. Commercial 2 Phase III 1
Karuna Therapeutics Inc. Commercial 2 Phase III 0
Geneora Pharma (Shijiazhuang) Co. Ltd. Academic 2 Other 0
Clexio Biosciences Ltd. Commercial 1 Phase I (Other) 0
Teva Branded Pharmaceutical Products R&D LLC Commercial 1 Phase I (Other) 0
Novartis Pharma AG Commercial 1 Phase II 0
Oryzon Genomics S.A. Commercial 1 Phase II 1
Recognify Life Sciences Inc. Commercial 1 Phase II 0
Newron Pharmaceuticals S.p.A. Commercial 1 Phase III 1
Institut National De La Sante Et De La Recherche Medicale Academic 1 Phase II/III 1
Klinikum der Universitaet Muenchen AöR Academic 1 Phase II 1
University Medical Center Utrecht Academic 1 Phase III 0
Masarykova Univerzita Academic 1 Phase IV 0
Universitair Medisch Centrum Utrecht Academic 1 Phase IV 1
New trials by year
2020
1
2021
2
2022
1
2023
5
2024
4
2025
6
2026
1
← All indication landscapes